河南羚锐制药股份有限公司 2024 年年度股东大会会议资料 二〇二五年四月二十六日 1 河南羚锐制药股份有限公司 2024 年年度股东大会议程 会议召集人：公司董事会 会议方式：现场投票表决与网络投票表决相结合的方式 现场会议召开时间：2025 年 5 月 20 日下午 14：00 网络投票时间为：采用上海证券交易所网络投票系统，通过交易系统投票平 台的投票时间为 2025 年 5 月 20 日 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为 2025 年 5 月 20 日 9:15-15:00。 现场会议召开地点：河南省新县将军路 666 号羚锐制药会议室 会议 主 持人：公司董事长 出席会议人员： 1、截止 2025 年 5 月 13 日下午交易结束后在中国证券登记结算有限责任公 司上海分公司登记在册的本公司全体股东；因故不能出席会议的股东可书面委托 代理人出席，该代理人不必是公司股东； 2、本公司董事、监事、高级管理人员； 3、公司聘请的律师。 会议议程： 1、2024 年度董事会工作报告 2 一、 主持人介绍到会情况并宣布大会开始； 二、 主持人提名 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2025-023 河南羚锐制药股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 20 日 14 点 00 分 召开地点：河南省新县将军路 666 号羚锐制药会议室 (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2025年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2024年年度股东大会 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 ...

证券简称：羚锐制药 证券代码：600285 公告编号：2025-017 号 河南羚锐制药股份有限公司 第九届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南羚锐制药股份有限公司第九届监事会第十三次会议于 2025 年 4 月 14 日 以通讯方式发出通知，并于 2025 年 4 月 24 日上午 8:30 在江南春温泉度假酒店 （河南省郑州荥阳市湖南中路）2 号楼 22 号会议室以现场方式召开，应参加会 议监事三名，实际参加三名。会议由监事会主席李进先生主持。会议的召集和召 开符合《中华人民共和国公司法》和《河南羚锐制药股份有限公司章程》的规定。 与会监事就会议议案进行了审议、表决，形成了如下决议： 一、审议通过《2024 年度监事会工作报告》 表决结果： 3 票赞成， 0 票反对， 0 票弃权 本议案尚需提交公司 2024 年年度股东大会审议批准。 二、审议通过《2024 年度利润分配预案》 详见上海证券交易所网站（http://www.sse.com.cn）公司同日披露的《河 南羚锐制药股份 ...

证券简称：羚锐制药 证券代码：600285 公告编号：2025-016 号 河南羚锐制药股份有限公司 第九届董事会第十五次会议决议公告 表决结果： 9 票赞成， 0 票反对， 0 票弃权 本议案尚需提交公司 2024 年年度股东大会审议批准。 四、审议通过《2024 年度财务决算报告》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南羚锐制药股份有限公司（以下简称"公司"）第九届董事会第十五次会 议于 2025 年 4 月 14 日以通讯方式发出通知,并于 2025 年 4 月 24 日上午 9:00 在江南春温泉度假酒店（河南省郑州荥阳市湖南中路）2 号楼 22 号会议室以现 场方式召开。会议应到董事 9 名,实到 9 名。会议的召集和召开符合《中华人民 共和国公司法》和《河南羚锐制药股份有限公司章程》的规定。与会董事就会议 议案进行了审议、表决，形成了如下决议： 一、审议通过《2024 年度董事会工作报告》 表决结果： 9 票赞成， 0 票反对， 0 票弃权 本议案尚需提交公司 2024 年年度股东大会审议批准。 二、 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2025-018 号 河南羚锐制药股份有限公司 2024 年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 每股分配比例：每股派发现金红利 0.90 元（含税），不进行资本公积金 转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，公司拟维持每股分配金额不变，相应调整分配总额，并将另行公告具 体调整情况。 本次利润分配方案不触及《上海证券交易所股票上市规则》第 9.8.1 条第 一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经大华会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司母公司报表中期末未分配利润为人民币 1,947,335,325.69 元。经董事会决议， 公司 2024 年年度拟以实施权益分派股权登记日登记的总股本为基数分配利润， 本次 ...

河南羚锐制药股份有限公司 内部控制审计报告 大华内字[2025]0011000088 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn)" 河南羚锐制药股份有限公司 内部控制审计报告 (截止 2024 年 12 月 31 日) 目 页 次 内部控制审计报告 一、、 を食計師事務所 十华会计师事务所 (特殊普通合伙) 舌:86 (10) 5835 0011 传真:86 (10) 内 部 控 制 审 计 报 告 大华内字[2025]0011000088 号 1-2 e 河南羚锐制药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了河南羚锐制药股份有限公司(以下简称羚锐制药) 2024年 12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 ...

河南羚锐制药股份有限公司 审计报告 大华审字[2025]0011007661 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) (2024 年 1 月 1 日至 2024 年 12 月 31 日止) | 目 | 求 | 页 次 | | --- | --- | --- | | 审计报告 | | 1-5 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | র্ব | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司股东权益变动表 | | 11-12 | | 财务报表附注 | | 1-97 | 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查理 河南羚锐制药股份有限公司 审计报告及财务报表 二、形成审计意见的基础 我们按照中国注册会计师 ...

非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位： 审计单位： 联系电话： 河南羚锐制药股份有限公司 控股股东及其他关联方资金占用情况的专项说明 (截止 2024年 12月 31 日) 目 录 关于河南羚锐制药股份有限公司 i í 河南羚锐制药股份有限公司 2024 年度非经营 1 性资金占用及其他关联资金往来情况汇总表 第1页 女生会计题事务所 (特殊普通合伙) 由海淀区西四五中路16号码 7号楼 12 层 : 86 (10) 5835 0011 传真: 86 (10) 58 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 大华核字[2025]0011003323 号 页 次 | I | 控股股东及其他关联方资金占用情况的专项 1-2 | | --- | --- | | | 说明 | 河南羚锐制药股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了河南羚 锐制药股份有限公司(以下简称羚锐制药)2024年度财务报表,包 括 2024年 12月 31 日的合并及母公司资产负债表,2024年度的 ...

Financial Performance - The company's operating revenue for 2024 reached ¥3,500,831,286.92, representing a year-on-year increase of 5.72% compared to ¥3,311,472,606.54 in 2023[24] - The net profit attributable to shareholders for 2024 was ¥722,550,720.15, a significant increase of 27.19% from ¥568,109,302.85 in the previous year[24] - The basic earnings per share for 2024 was ¥1.287, up 27.17% from ¥1.012 in 2023[26] - The company's total assets as of the end of 2024 amounted to ¥5,016,843,207.73, reflecting a 5.13% increase from ¥4,771,917,373.39 at the end of 2023[25] - The net assets attributable to shareholders increased by 10.09% to ¥3,072,526,287.29 at the end of 2024, compared to ¥2,791,040,844.65 at the end of 2023[25] - The company reported a net cash flow from operating activities of ¥875,864,233.13 for 2024, an increase of 7.68% from ¥813,428,748.87 in 2023[24] - The weighted average return on equity for 2024 was 24.80%, an increase of 3.52 percentage points from 21.28% in 2023[26] Dividend Policy - The company plans to distribute a cash dividend of ¥0.90 per share, totaling approximately ¥510,403,937.40, which accounts for 70.64% of the annual net profit attributable to shareholders[6] - The total number of shares for the cash dividend distribution is 567,115,486, with a cash dividend payout of ¥451,147,133.60 for the fiscal year 2023, based on a total share capital of 567,140,242 shares[159] - Over the last three accounting years, the cumulative cash dividend amount (including tax) reached ¥1,300,007,084.00, with an average annual net profit of ¥585,321,539.03, resulting in a cash dividend ratio of 222.10%[167] - The company has established a three-year shareholder dividend return plan for 2024-2026 to ensure a stable and predictable return mechanism for investors[158] - The company has not proposed a stock dividend or capital reserve transfer to increase share capital for the fiscal year 2024, opting to carry forward the remaining distributable profits to the next year[160] Research and Development - The company has accelerated its digital and intelligent upgrades, enhancing management efficiency through automation technologies[35] - The company is focusing on research and development in major disease areas, including orthopedics and respiratory systems, to strengthen its product line[36] - Research and development expenses increased by 19.95% to 131.53 million RMB, indicating a focus on innovation[68] - The company reported a significant increase in R&D expenditures for projects LR003, LR015, LR002, and LR020, with year-on-year increases of 41.99%, 126.73%, 366.43%, and 362.85% respectively[109] - The company plans to prioritize R&D innovation in traditional Chinese medicine and high-end formulations, particularly in orthopedics and chronic disease management[120] Product Development and Market Strategy - The company completed the construction of production lines for tablets and oral liquid formulations at its Xinyang branch, laying the foundation for future product expansion[35] - The company obtained drug registration certificates for new products, including Montelukast Sodium Chewable Tablets and Metformin Hydrochloride Sustained-Release Tablets[36] - The company signed a letter of intent to acquire controlling interest in Yingu Pharmaceutical Co., Ltd., enhancing its product matrix with high-tech external preparations[37] - The company launched new products such as Tadalafil tablets and Montmorillonite powder, contributing to its growth momentum during the reporting period[39] - The company is focusing on expanding its product lineup in major therapeutic areas such as orthopedics, respiratory, dermatology, and digestive systems[98] Market Presence and Brand Recognition - The company’s pediatric brand "Little Antelope" is being promoted through major media channels, including CCTV and social media, to deepen brand awareness[38] - The company’s "Two Tigers" brand won the Best-Selling Brand Award in the Chinese drug retail market for 2024, indicating strong brand recognition[38] - The company has developed nearly 5,000 hospitals and grassroots medical institutions for its prescription drug business, enhancing its market presence[39] - The company’s unique product, Tongluo Qutong Ointment, is included in the National Essential Drug List and National Medical Insurance Directory, highlighting its market position in orthopedics[61] Operational Efficiency and Management - The company emphasizes a strict supplier management system to ensure the quality and stability of raw material supplies, which is crucial for production[58] - The company follows a "sales-driven production" model, aligning production tasks with market demand and inventory levels to optimize efficiency[59] - The company has a diverse sales model that includes distribution and direct sales, leveraging e-commerce platforms for product promotion[59] - The company is advancing its smart manufacturing capabilities, integrating modern information management systems to enhance production efficiency[65] Risk Management and Compliance - The company does not foresee any significant risks that could materially impact its operations during the reporting period[9] - The company will strengthen its internal control systems to mitigate risks and enhance overall risk management capabilities[119] - The company anticipates potential risks from policy changes in the pharmaceutical industry, emphasizing the need for enhanced management and compliance[126] - The company will implement strict quality management systems to mitigate risks associated with product quality and ensure compliance with national regulations[127] Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and regulations while enhancing operational quality[130] - The company’s board of directors operates effectively, with clear responsibilities and adherence to legal requirements, ensuring independent oversight of management activities[132] - The company has established a comprehensive internal control system covering governance, management, finance, human resources, and auditing[133] - The company’s annual financial report received an unqualified opinion, indicating transparency and adherence to disclosure requirements[133] Social Responsibility and Environmental Impact - The company invested 1.1414 million yuan in environmental protection during the reporting period[177] - The company has reported a total donation of 2.1541 million yuan for public welfare projects, including 0.9030 million yuan in cash and 1.2511 million yuan in material donations[185] - The company has implemented measures to reduce carbon emissions, including regular analysis of energy consumption and promoting water conservation[184] - The company has completed the installation and acceptance of video monitoring and online monitoring equipment for wastewater discharge[179]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,020,755,870.55, representing a 12.29% increase compared to CNY 909,046,867.70 in the same period last year[3]. - The net profit attributable to shareholders was CNY 216,817,540.12, up 13.89% from CNY 190,378,639.92 year-on-year[3]. - Basic earnings per share rose to CNY 0.383, a 12.65% increase from CNY 0.340 in the same period last year[3]. - Total operating revenue for Q1 2025 reached ¥1,020,755,870.55, an increase of 12.3% compared to ¥909,046,867.70 in Q1 2024[18]. - Net profit for Q1 2025 was ¥216,733,789.10, representing a 13.9% increase from ¥190,328,634.98 in Q1 2024[19]. - Basic earnings per share for Q1 2025 were ¥0.383, compared to ¥0.340 in Q1 2024, indicating a growth of 12.6%[20]. - The company reported a comprehensive income total of ¥223,044,911.33 for Q1 2025, compared to ¥140,894,063.49 in Q1 2024, reflecting a significant increase of 58.3%[20]. Cash Flow - The net cash flow from operating activities increased significantly by 161.91%, reaching CNY 117,615,900.12, compared to CNY 44,906,293.79 in the previous year[3]. - Cash received from sales of goods and services in Q1 2025 was ¥895,511,232.10, an increase from ¥761,878,217.97 in Q1 2024, marking a growth of 17.5%[22]. - Operating cash inflow totaled $903,232,099.55, an increase from $809,623,301.08 in the previous period[23]. - Net cash flow from operating activities reached $117,615,900.12, significantly up from $44,906,293.79[23]. - The ending cash and cash equivalents balance was $570,929,618.67, down from $1,466,278,009.71[24]. - The company experienced a net decrease in cash and cash equivalents of $657,448,187.33 during the period[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,410,895,780.92, reflecting a 7.85% increase from CNY 5,016,843,207.73 at the end of the previous year[4]. - Total liabilities rose to ¥2,067,027,296.35, compared to ¥1,936,551,143.73 in the previous period, reflecting an increase of 6.8%[14]. - The total equity attributable to shareholders was CNY 3,311,522,505.91, which is a 7.78% increase from CNY 3,072,526,287.29[4]. - Shareholders' equity increased to ¥3,343,868,484.57, up from ¥3,080,292,064.00, indicating a growth of 8.6%[15]. Investments and Acquisitions - The company approved the acquisition of 90% equity in Yingu Pharmaceutical Co., Ltd. for RMB 703,908,000, which was completed in March 2025[10]. - The company's intangible assets increased significantly from RMB 203,746,216.32 to RMB 317,123,551.29, marking an increase of approximately 55.5%[13]. - The goodwill recorded as of March 31, 2025, was RMB 482,016,236.04, indicating the company's strategic investments in acquisitions[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,288[8]. - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 121,817,898 shares, accounting for 21.48% of the total shares, with 26,930,000 shares pledged[8]. - The company has not reported any changes in the top 10 shareholders or their participation in margin financing and securities lending activities[10]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥780,335,122.23, up from ¥696,497,752.04 in Q1 2024, reflecting a growth of 12.0%[18]. - Research and development expenses for Q1 2025 were ¥22,799,572.17, compared to ¥20,393,113.38 in Q1 2024, showing an increase of 11.8%[19].